The U.S. breast imaging and mammography markets are expected to not only recover from the recession, but nearly double in the next several years.
The U.S. breast imaging and mammography markets are expected to not only recover from the recession, but nearly double in the next several years.
By 2017, the markets are expected to reach more than $1 billion, according to a new report by iData Research, a medical device and pharmaceutical market research company. The growth is expected to be driven by the replacement of older analog equipment with technologies such as digital radiography, breast-specific gamma imaging, positron emission mammography, and ultrasound equipment.
Leading the overall $2.3 billion women’s health market with sales of digital radiography equipment are Hologic and GE Healthcare, the report found. The development of breast-specific gamma imaging by Dilon Technologies and Gamma Medical, and positron emission mammography by Naviscan mean a new market for breast scans, and these technologies will experience “rapid growth,” according to Dr. Kamran Zamanian, CEO of iData.
“The majority of analog units used in 2010 are expected to be replaced by 2017,” Zamanian said in a statement.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.